The use of baseline covariates in crossover studies

Biostatistics

Volumn 11, Issue 1, 2010, Pages 1-17

  Kenward, Michael G ^a   Roger, James H ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Analysis of covariance; Causal pathway; Covariance structure; Cross level bias; Experimental design; REML; Restricted maximum likelihood

Indexed keywords

ANTIHYPERTENSIVE AGENT; HETEROCYCLIC COMPOUND; MOXIFLOXACIN; NITRIC OXIDE; QUINOLINE DERIVATIVE;

ALGORITHM; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; BRONCHUS HYPERREACTIVITY; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAM; EPIDEMIOLOGY; FORCED EXPIRATORY VOLUME; HEART DISEASE; HUMAN; HYPERTENSION; METABOLISM; METHODOLOGY; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICAL DISTRIBUTION; STATISTICAL MODEL;

ALGORITHMS; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; AZA COMPOUNDS; BIAS (EPIDEMIOLOGY); BLOOD PRESSURE; BRONCHIAL HYPERREACTIVITY; CONTROLLED CLINICAL TRIALS AS TOPIC; CROSS-OVER STUDIES; ELECTROCARDIOGRAM PATTERN; EPIDEMIOLOGIC RESEARCH DESIGN; FORCED EXPIRATORY VOLUME; HEART DISEASES; HUMANS; HYPERTENSION; LIKELIHOOD FUNCTIONS; MODELS, STATISTICAL; NITRIC OXIDE; PAIN; QUINOLINES; STATISTICAL DISTRIBUTIONS;

EID: 72649088429     PISSN: 14654644     EISSN: 14684357     Source Type: Journal    
DOI: 10.1093/biostatistics/kxp046     Document Type: Article

References (16)

1. CARPENTER, J. R. AND KENWARD, M. G. (2008). Missing Data in Randomised Controlled Trials-A Practical Guide. http://www.pcpoh.bham.ac.uk/publichealth/ nccrm/PDFs and documents/Publications/Final Report RM04 JH17 mk.pdf.
2. FREEMAN, P. (1989). The performance of the two-stage analysis of two-treatment, two-period cross-over trials. Statistics in Medicine 8, 1421-1432.
3. GALWEY, (2006). Introduction to Mixed Modelling: Beyond Regression and Analysis of Variance. Chichester: Wiley.
4. GOLDSTEIN, H. (1987). Multilevel Models. London: Charles Griffin & Co.
5. GREENLAND, S., PEARL, J. AND ROBINS, J. M. (1999). Causal diagrams for epidemiologic research. Epidemiology 10, 37-48.
6. JONES, B. AND KENWARD, M. G. (2003). Design and Analysis of Cross-over Trials, 2nd edition. London: Chapman & Hall/CRC.
7. KENWARD, M. G. AND JONES, B. (1987). The analysis of data from 2x2 cross-over trials with baseline measurements. Statistics in Medicine 6, 911-926.
8. KENWARD, M. G. AND ROGER, J. H. (1997). Small sample inference for fixed effects estimators from restricted maximum likelihood. Biometrics 53, 983-997.
9. KENWARD, M. G. AND ROGER, J. H. (2009). An improved approximation to the precision of fixed effects from restricted maximum likelihood. Computational Statistics and Data Analysis 53, 2583-2595.
10. MCCANN, D., BARRETT, A., COOPER, A., CRUMPLER, D., DALEN, L., GRIMSHAW, K., KITCHIN, E., LOK, K., PORTEOUS, L., PRINCE, E. and others (2007). Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. The Lancet 370, 1560-1567.
11. POCOCK, S. J., ASSMANN, S. E., ENOS, L. E. AND KASTEN, L. E. (2002). Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: curent practice and problems. Statistics in Medicine 21, 2917-2930.
12. SENN, S. J. (1988). Cross-over trials, carry-over effects and the art of self-delusion. Statistics in Medicine 7, 1099-1101.
13. SENN, S. J. (2002) Cross-over Trials in Clinical Research, 2nd edition. Chichester: Wiley.
14. SHEPPARD, L. (2003) Insights on bias and information in group-level studies. Biostatistics 4, 265-278.
15. SKRONDAL, A. AND RABE-HESKETH, S. (2004). Generalized Latent Variable Modelling. London: Chapman & Hall/CRC.
16. STYLIANOU, A., ROGER, J. AND STEPHENS, K. (2008). A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QR studies. Journal of Biopharmaceutical Statistics 18, 502-516.